The Study of Pharmacological Treatment Pattern for Cannabis-induced Psychosis

NCT04945031 | Completed FDA Drug

• 1 other identifier: MU-DT/PY-IRB2019/PY114
• Study Type: observational
• Target: 317
• Locations: 1 country
• Sites: 1

Brief Summary

A cross-sectional and retrospective chart review study was conducted at the Princess Mother National Institute on Drug Abuse Treatment (PMNIDAT), Thailand. All patients who admitted at PMNIDAT from October 2013 to September 2019 were included. Patients aged 18-65 years who met the International Classification of Disease-10 (ICD-10) criteria of CIP and Had a positive urine test of cannabis were included. Cannabis use is a component cause of psychosis.More than half of symptoms of cannabis-induced psychosis (CIP) were hallucination, delusion, irritable and anxiety. Antipsychotic drug was still a key psychotropic drugs for treatment of CIP. However, antidepressants and benzodiazepines were commonly used for treatment of other symptoms beyond psychotics

Conditions

Cannabis

Outcome Measures

Primary Outcomes (1)

• Pharmacological treatment pattern for cannabis-induced psychosis

  Pharmacological treatment pattern for cannabis-induced psychosis during admission

  30 days

Secondary Outcomes (1)

• Change of Brief psychiatric rating scale (BPRS) form the first day of admission

  Day1, Day 8, Day 15 and Day 22

Study Arms (1)

cannabis-induced psychosis

Other: cannabis

Interventions

cannabis OTHER

This study is observational study, we recorded history of substance used, symptoms and medication in a medical chart.

cannabis-induced psychosis

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Medical chart which diagnosis by ICD-10 with cannabis-induced psychosis who admitted at PMNIDAT from October 2013 to September 2019 at Princess Mother National Institute on Drug Abuse Treatment.

You may qualify if:

• Patients ≥ 12 years of age
• Patients who had been diagnosed as Cannabis-induced psychosis by International statistical Classification of Disease and Related Health problem (ICD-10) on 2016 code F12.5
• Patients had history of use of cannabis in medical chart
• Patients had the positive urine screening test of cannabis at the first day of admission

You may not qualify if:

• Patients had psychosis from organic psychosis, defined by diagnosis by ICD-10 code F09.6
• Unavailable data for evaluate of outcome especially data of drug use, content of drug use or urine screening test
• Patients who cancel of medical treatment before 7 day after admission.

Sponsors & Collaborators

• Mahidol University: lead

Study Sites (1)

Onrumpha Chuenchom

Thanyaburi, Changwat Pathum Thani, 12110, Thailand

Location

Related Publications (1)

• Chuenchom O, Suansanae T, Lukanapichonchut L, Suwanmajo S, Suthisisang C. Real world clinical outcomes of treatment of cannabis-induced psychosis and prevalence of cannabis-related primary psychosis: a retrospective study. BMC Psychiatry. 2024 Sep 27;24(1):626. doi: 10.1186/s12888-024-06075-6.

  PMID: 39334053 DERIVED

MeSH Terms

Conditions

Marijuana Abuse

Interventions

nabiximols

Condition Hierarchy (Ancestors)

Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 15, 2021
• First Posted: June 30, 2021
• Study Start: November 8, 2019
• Primary Completion: May 31, 2020
• Study Completion: December 31, 2020
• Last Updated: June 30, 2021

Record last verified: 2021-06

Locations

TH (1)